RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Feb 19, 2013 - 1:22:36 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
USAID awards cooperative agreement to CONRAD for multipurpose prevention study

Oct 13, 2011 - 4:00:00 AM
Almost half of all pregnancies worldwide, estimated to be over 100 million annually, are unintended. In 2008, this resulted in 43 million abortions, half of which were performed under unsafe conditions, leading to almost 100,000 maternal deaths and 5 million women left with temporary or permanent disabilities. The majority of these deaths occur in less developed countries where the AIDS epidemic is most prevalent.

 
[RxPG] Arlington, VA -- USAID awarded CONRAD a five year project with a $2 million ceiling to focus on testing the safety and effectiveness of the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined with tenofovir gel -- the only topical product proven to prevent the acquisition of HIV and Herpes Simplex Virus (HSV). If shown to be safe, effective and acceptable, this combination of products would provide women with a non-hormonal contraceptive method under their own control that also delivers protection against HIV and HSV. This award supports Aim 2 of USAID's Biomedical Research for Reproductive Health: to fast track development of reproductive health technologies that can simultaneously prevent unintended pregnancy, HIV, and other sexually transmitted infections.

Results of the SILCS diaphragm contraceptive effectiveness study were announced last month and showed effectiveness rates similar to that of a traditional fitted diaphragm. The benefits of this single size diaphragm include eliminating the need for a pelvic exam to fit the diaphragm, and meeting the contraceptive needs of women unable or unwilling to use a hormonal method.

In a recent landmark effectiveness trial conducted by CAPRISA in South Africa, tenofovir gel was shown to reduce the risk of HIV infection by 39% and HSV by 51%. Confirmatory studies of the gel are ongoing and will support regulatory approval.

Dr. Henry Gabelnick, CONRAD's Executive Director said, We see an urgent need for multipurpose prevention technologies, including non-hormonal methods that are easy to use, and that can be combined with a product that reduces the risk of HIV and HSV infection. This type of reproductive health technology is particularly needed in areas of the world where women need easy to use methods that are within their control.

Almost half of all pregnancies worldwide, estimated to be over 100 million annually, are unintended. In 2008, this resulted in 43 million abortions, half of which were performed under unsafe conditions, leading to almost 100,000 maternal deaths and 5 million women left with temporary or permanent disabilities. The majority of these deaths occur in less developed countries where the AIDS epidemic is most prevalent.

The SILCS diaphragm was developed at PATH, an international nonprofit organization whose mission is to improve the health of people around the world. PATH and CONRAD have collaborated on the validation of the SILC diaphragm for regulatory approval as a contraceptive device. CONRAD has been developing new methods of contraception for men and women for 25 years, including hormonal methods and barrier devices such as the female condom and cervical caps.



Related Latest Research News
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Book explores undiscovered economics of everyday life

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)